CI-1033, an Irreversible pan-erbB Receptor Inhibitor and its Potential Application for the Treatment of Breast Cancer

Seminars in Oncology

Volumn 30, Issue 5 SUPPL. 16, 2003, Pages 65-78

  Allen, Lee F ^a   Eiseman, Irene A ^a   Fry, David W ^a   Lenehan, Peter F ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CANERTINIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CL 1033; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; INSULIN RECEPTOR; METHOTREXATE; NAVELBINE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; BRONCHOSPASM; CANCER GROWTH; CARDIOTOXICITY; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DYSPNEA; EDEMA; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NAUSEA; ONCOGENE NEU; PATHOGENESIS; PRIORITY JOURNAL; RASH; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; URTICARIA; VOMITING; WESTERN BLOTTING;

EID: 0242721567     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.08.009     Document Type: Conference Paper

References (100)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
2. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103:211-225, 2000
3. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
4. Klapper LN, Kirschbaum MH, Sela M, et al: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77:25-79, 2000
5. Olayioye MA, Neve RM, Lane HA, et al: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19:3159-3167, 2000
6. Bucci B, D'Agnano I, Botti C, et al: EGF-R expression in ductal breast cancer: Proliferation and prognostic implications. Anticancer Res 17:769-774, 1997
7. Fox SB, Smith K, Hollyer J, et al: The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 29:41-49, 1994
8. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001
9. Ullrich A, Coussens L, Hayflick JS, et al: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418-425, 1984
10. Kirschbaum MH, Yarden Y: The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms. J Cell Biochem Suppl 34:52-60, 2000
11. Kim H, Muller WJ: The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res 253:78-87, 1999
12. Salomon DS, Bianco C, De Santis M: Cripto: A novel epidermal growth factor (EGF)- related peptide in mammary gland development and neoplasia. Bioessays 21:61-70, 1999
13. Pawlowski V, Revillion F, Hebbar M, et al: Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6:4217-4225, 2000
14. Gullick WJ, Srinivasan R: The type 1 growth factor receptor family: New ligands and receptors and their role in breast cancer. Breast Cancer Res Treat 52:43-53, 1998
15. Tang CK, Lippman ME: EGF family receptors and their ligands in human cancer. Horm Signaling 1:113-165, 1998
16. Klijn JG, Berns PM, Schmitz PI, et al: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr Rev 13:3-17, 1992
17. Tang CK, Gong XO, Moscatello DK, et al: Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 60:3081-3087, 2000
18. Gullick WJ: The c-erbB3/HER3 receptor in human cancer. Cancer Surv 27:339-349, 1996
19. Bodey B, Bodey B Jr, Groger AM, et al: Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 17:1319-1330, 1997
20. Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791-808, 1998
21. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
22. Pinkas-Kramarski R, Soussan L, Waterman H, et al: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467, 1996
23. Alimandi M, Romano A, Curia MC, et al: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-1821, 1995
24. Zhang K, Sun J, Liu N, et al: Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 271:3884-3890, 1996
25. Gilbertson RJ, Perry RH, Kelly PJ, et al: Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57:3272-3280, 1997
26. He Y, Zeng Q, Drenning SD, et al: Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 90:1080-1087, 1998
27. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-6565, 2000
28. Azemar M, Schmidt M, Arlt F, et al: Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer 86:269-275, 2000
29. Anderson NG, Ahmad T: ErbB receptor tyrosine kinase inhibitors as therapeutic agents. Front Biosci 7:d1926-d1940, 2002
30. Goldenberg MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21:309-318, 1999
31. DiAugustine RP, Richards RG, Sebastian J: EGF-related peptides and their receptors in mammary gland development. J Mammary Gland Biol Neoplasia 2:109-117, 1997
32. Ratcliffe N, Wells W, Wheeler K, et al: The combination of in situ hybridization and immunohistochemical analysis: An evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium. Mod Pathol 10:1247-1252, 1997
33. Dittadi R, Donisi PM, Brazzale A, et al: Epidermal growth factor receptor in breast cancer. Comparison with non malignant breast tissue. Br J Cancer 67:7-9, 1993
34. Lemoine NR, Barnes DM, Hollywood DP, et al: Expression of the ERBB3 gene product in breast cancer. Br J Cancer 66:1116-1121, 1992
35. Downward J, Yarden Y, Mayes E, et al: Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307:521-527, 1984
36. Libermann TA, Nusbaum HR, Razon N, et al: Amplification enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313:144-147, 1985
37. Ciardiello F: Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60:25-32, discussion 41-42, 2000 (suppl 1)
38. Chu CT, Everiss KD, Wikstrand CJ, et al: Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor receptor (EGFR-vIII). Biochem J 324:855-861, 1997
39. Nagane M, Coufal F, Lin H, et al: A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079-5086, 1996
40. Nishikawa R, Ji XD, Harmon RC, et al: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91:7727-7731, 1994
41. Kraus MH, Popescu NC, Amsbaugh SC, et al: Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6:605-610, 1987
42. Torre EA, Salimbeni V, Fulco RA: The erbB2 oncogene and chemotherapy: A mini-review. J Chemother 9:51-55, 1997
43. Tetu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 73:2359-2365, 1994
44. Stal O, Sullivan S, Wingren S, et al: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A:2185-2190, 1995
45. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
46. Shak S: Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 26:71-77, 1999 (suppl 12)
47. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neumonoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
48. Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/ neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998
49. Cobleigh MA, Vogel CL, Tripathy D, et al: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 17:97a, 1998 (abstr 376)
50. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
51. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-everexpressing metastatic breast cancer. Semin Oncol 26:78-83, 1999 (suppl 12)
52. Ewer MS, Gibbs HR, Swafford J, et al: Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 26:96-101, 1999.(suppl 12)
53. Siegel PM, Ryan ED, Cardiff RD, et al: Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer. EMBO J 18:2149-2164, 1999
54. Knowlden JM, Gee JM, Seery LT, et al: c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17:1949-1957, 1998
55. Naidu R, Yadav M, Nair S, et al: Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 78:1385-1390, 1998
56. Travis A, Pinder SE, Robertson JF, et al: C-erbB-3 in human breast carcinoma: Expression and relation to prognosis and established prognostic indicators. Br J Cancer 74:229-233, 1996
57. Suo Z, Risberg B, Kalsson MG, et al: EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196:17-25, 2002
58. Plowman GD, et al: Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A 90:1746-1750, 1993
59. Zhou W, Carpenter G: ErbB-4: A receptor tyrosine kinase. Inflamm Res 51:91-101, 2002
60. Gassmann M, Casagranda F, Orioli D, et al: Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378:390-394, 1995
61. Jones FE, Welte T, Fu XY, et al: ErbB4 signaling in the mammary gland is required for labuloalveolar development and Stat5 activation during lactation. J Cell Biol 147:77-78, 1999
62. Vogt U, Bielawski K, Schlotter CM, et al: Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. Gene 223:375-380, 1998
63. Srinivasan R, Poulsom R, Hurst HC, et al: Expression of the c-erbB-4/ HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 185:236-245, 1998
64. Srinivasan R, Gillett CE, Barnes DM, et al: Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 60:1483-1487, 2000
65. Kew TY, Bell JA, Pinder SE, et al: c-erbB-4 protein expression in human breast cancer. Br J Cancer 82:1163-1170, 2000
66. Tang CK, Concepcion XZ, Milan M, et al: Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res 59:5315-5322, 1999
67. Gilmour LM, Macleod KG, McCaig A, et al: Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. Cancer Res 61:2169-2176, 2001
68. Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410:83-86, 1997
69. Riese DJ II, Stern DF: Specificity within the EGF family/ ErbB receptor family signaling network. Bioessays 20:41-48, 1998
70. Grant S, Qiao L, Dent P: Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 7:d376-d389, 2002
71. Amundadottir LT, Leder P: Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 16:737-746, 1998
72. Zwick E, Bange J, Ullrich A: Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8:17-23, 2002
73. Kairouz R, Daly RJ: Tyrosine kinase signalling in breast cancer: Modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates. Breast Cancer Res 2:197-202, 2000
74. Tzahar E, Waterman H, Chen X, et al: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287, 1996
75. Klapper LN, Glathe S, Vaisman N, et al: The ErbB-2/ HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 96:4995-5000, 1999
76. Waterman H, Alroy I, Strano S, et al: The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. EMBO J 18:3348-3358, 1999
77. Qian X, Dougall WC, Fei Z, et al: Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation. Oncogene 10:211-219, 1995
78. Sundaresan S, Roberts PE, King KL, et al: Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology 139:4756-4764, 1998
79. Brandt BH, Roetger A, Dittmar T, et al: c-erbB-2/EGFR as dominant heterodimerization partners determine a mitogenic phenotype in human breast cancer cells. FASEB J 13: 1939-1949, 1999
80. Xia W, Lau YK, Zhang HZ, et al: Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5:4164-4174, 1999
81. Normanno N, Bianco C, De Luca A, et al: The role of EGF-related peptides in tumor growth. Front Biosci 1:D685-D707, 2001
82. Fedi P, Kimmelman A, Aaronson SA: Growth factor signal transduction in cancer, in Holland J, Frei T III, Bast R Jr, et al (eds): Cancer Medicine (5th ed). Malvern, PA, Lea & Febiger, 2000, pp 33-55
83. Tzahar E, Pinkas-Kramarski R, Moyer JD, et al: Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 16:4938-4950, 1997
84. Shelly M, Pinkus-Kramarski R, Guarino BC, et al: Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem 273:10496-10505, 1998
85. Grace EA, Rabiner CA, Busciglio J: Characterization of neuronal dystrophy induced by fibrillar amyloid beta: Implications for Alzheimer's disease. Neuroscience 114:265-273, 2002
86. Baselga J: Targeting the epidermal growth factor receptor: A clinical reality. J Clin Oncol 19:41S-44S, 2001 (suppl)
87. Levitzki A: Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther 82:231-239, 1999
88. Fry DW: Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 82:207-218, 1999
89. Fry DW, Bridges AJ, Denny WA, et al: Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci U S A 95:12022-12027, 1998
90. Fry DW: Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des 15:3-16, 2000
91. Arteaga CL, Ramsey TT, Shawver LK, et al: Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem 272:23247-23254, 1997
92. Lichtner RB, Menrad A, Sommer A, et al: Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 61:5790-5795, 2001
93. Allen LF, Lenehan PF, Eiseman IA, et al: Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 29:11-21, 2002 (suppl 11)
94. Rao GS, Murray S, Ethier SP: Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Intl J Radiat Oncol Biol Phys 48: 1519-1528, 2000
95. Gieseg MA, de Bock C, Ferguson LR, et al: Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs 12:683-690, 2001
96. Garrison MA, Tolcher A, McCreery H, et al: A phase 1 and pharmacokinetic study of CI-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors. Proc Am Soc Clin Oncol 20:72a, 2001 (abstr 283)
97. Rinehart JJ, Wilding G, Willson J, et al: A phase 1 clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 21:11a, 2002 (abstr 41)
98. Zinner RG, Nemunaitis JJ, Donato NJ, et al: A phase I clinical and biomarker study of the novel pan-erbB tyrosine inhibitor, CI-1033 in patients with solid tumors. Clin Cancer Res 7:3767s-3768s, 2001 (abstr 566) (suppl)
99. Shin DM, Nemunaitis J, Zinner RG, et al: A phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors. Proc Am Soc Clin Oncol 20:82a, 2001 (abstr 324)
100. Burton A: What went wrong with Iressa? Lancet Oncol 3:708, 2002